Stem Cell Mobilization Treatment Gets Orphan Status from FDA – Drug Discovery & Development
| Drug Discovery & Development The Orphan Drug Designation was granted for use of BL-8040, in combination with granulocyte colony-stimulating factor (G-CSF), to mobilize human stem cells from the bone marrow to the peripheral blood for collection for autologous or allogeneic … BioLineRx gains orphan status for novel stem cell mobilization treatmentThe Pharma Letter |
